Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: Quality-of-life analyses of the METRIC study

Annals of Oncology

Volumn 25, Issue 3, 2014, Pages 700-706

  Schadendorf, D ^a   Amonkar, M M ^b   Milhem, M ^c   Grotzinger, K ^b   Demidov, L V ^d   Rutkowski, P ^e   Garbe, C ^f   Dummer, R ^g   Hassel, J C ^h   Wolter, P ⁱ   Mohr, P ^j   Trefzer, U ^k   Lefeuvre Plesse, C ^l   Rutten, A ^m   Steven, N ⁿ   Ullenhag, G ^o   Sherman, L ^b   Wu, F S ^b   Patel, K ^b   Casey, M ^b   Robert, C ^p   more..

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b GLAXOSMITHKLINE   (United States)

^c UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^d N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

^e INSTITUTE OF ONCOLOGY   (Poland)

^f UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^g UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^h UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

ⁱ UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^j Elbekliniken ^*  (Germany)

^k CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^l CENTRE EUGÈNE MARQUIS   (France)

^m SINT AUGUSTINUS HOSPITAL   (Belgium)

ⁿ QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^o UPPSALA UNIVERSITY   (Sweden)

^p INSTITUT GUSTAVE ROUSSY   (France)

more..

Author keywords

BRAF; Chemotherapy; MEK; Melanoma; Quality of life; Trametinib

Indexed keywords

DACARBAZINE; PACLITAXEL; TRAMETINIB;

ARTICLE; CANCER CHEMOTHERAPY; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE EXACERBATION; DYSPNEA; EMOTIONALITY; EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER QUALITY OF LIFE QUESTIONNAIRE; FATIGUE; FOLLOW UP; HEALTH STATUS; HUMAN; INSOMNIA; LOSS OF APPETITE; METASTATIC MELANOMA; NAUSEA AND VOMITING; PAIN; PHYSICAL PERFORMANCE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; SELF REPORT; SOCIAL INTERACTION;

BRAF; CHEMOTHERAPY; MEK; MELANOMA; QUALITY OF LIFE; TRAMETINIB;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DACARBAZINE; DISEASE-FREE SURVIVAL; HEALTH STATUS; HUMANS; MAP KINASE KINASE KINASES; MELANOMA; MIDDLE AGED; MUTATION; PACLITAXEL; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; PYRIDONES; PYRIMIDINONES; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 84896823405     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt580     Document Type: Article

References (17)

1. Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-954.
2. Jakob JA, Bassett RL, Jr, Ng CS et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 2012; 118: 4014-4023.
3. Montagut C, Settleman J. Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Lett 2009; 283: 125-134.
4. Flaherty KT, Robert C, Hersey P et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012; 367: 107-114.
5. European Organisation for Research and Treatment of Cancer. EORTC quality of life questionnaire (EORTC QLQ-C30). http://groups.eortc.be/qol/eortc-qlq-c30.
6. Aaronson NK, Ahmedzai S, Bergman B et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-376.
7. European Organisation for Research and Treatment of Cancer; Scott NW, Fayers PM, Aaronson NK et al. EORTC QLQ-C30 reference values. http://groups.eortc.be/qol/sites/default/files/img/newsletter/reference_values_manual2008.pdf.
8. Osoba D, Rodrigues G, Myles J et al. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998; 16: 139-144.
9. Al-Shakhli H, Harcourt D, Kenealy J. Psychological distress surrounding diagnosis of malignant and nonmalignant skin lesions at a pigmented lesion clinic. J Plast Reconstr Aesthet Surg 2006; 59: 479-486.
10. Newton-Bishop JA, Nolan C, Turner F et al. A quality-of-life study in high-risk (thickness ≥or 2 mm) cutaneous melanoma patients in a randomized trial of 1-cm versus 3-cm surgical excision margins. J Investig Dermatol Symp Proc 2004; 9: 152-159.
11. Kotapati S, Francis S, Sherrill B. Health related quality of life (HRQL) of patients receiving ipilimumab with dacarbazine as first-line treatment for unresectable stage III/IV melanoma. Pigment Cell Melanoma Res 2011; 24: 1037. abstr SMRP50.
12. Revicki DA, van den Eertwegh AJ, Lorigan P et al. Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment. Health Qual Life Outcomes 2012; 10: 66.
13. Grob J, Algarra SM, Amonkar MM et al. Dabrafenib vs dacarbazine (DTIC) in patients with BRAF V600+ advanced and metastatic melanoma in BREAK-3: quality of life (QOL) analysis. Pigment Cell Melanoma Res 2013; 26: 152.
14. Osoba D, Aaronson N, Zee B et al. Modification of the EORTC QLQ-C30 (version 2.0) based on content validity and reliability testing in large samples of patients with cancer. The Study Group on Quality of Life of the EORTC and the Symptom Control and Quality of Life Committees of the NCI of Canada Clinical Trials Group. Qual Life Res 1997; 6: 103-108.
15. Osoba D, Zee B, Pater J et al. Psychometric properties and responsiveness of the EORTC Quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer. Qual Life Res 1994; 3: 353-364.
16. Hjermstad MJ, Fossa SD, Bjordal K et al. Test/retest study of the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire. J Clin Oncol 1995; 13: 1249-1254.
17. Kaasa S, Bjordal K, Aaronson N et al. The EORTC Core Quality of Life Questionnaire (QLQ-C30): validity and reliability when analysed with patients treated with palliative radiotherapy. Eur J Cancer 1995; 31A: 2260-2263.